Press Releases

PRESS RELEASE February 20, 2018

Immune Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders and Provides Business Update

5 of 6 proposals pass with shareholder approval Meeting adjourned solely with respect to Proposal 4 – Ratification of the Reverse Stock Split Company outlines key corporate and clinical milestones for 201 Englewood Cliffs, NJ (February 20, 2018) – Immune Pharmaceuticals, Inc. (NASDAQ; IMNP) (“Immune” or the “Company”) a biopharmaceutical company developing novel therapeutic agents […]

Keep Reading

PRESS RELEASE February 6, 2018

Immune Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 12, 2018

Englewood Cliffs, NJ- February 6, 2018 – Immune Pharmaceuticals Inc. (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that its CEO, Elliot Maza, will present at the BIO CEO & Investor Conference, to be held February 12-13 at the New York Marriott Marquis in New York, […]

Keep Reading

PRESS RELEASE January 26, 2018

Immune Pharmaceuticals Announces Adjournment of Annual Meeting

Annual Meeting to Resume Thursday, February 15, 2018 Englewood Cliffs, NJ – January 26, 2018 – Immune Pharmaceuticals Inc. (NASDAQ: IMNP), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that it adjourned its Annual Meeting of Stockholders, scheduled for and convened on January 25, 2018. The […]

Keep Reading

PRESS RELEASE January 23, 2018

Immune Pharmaceuticals to Present at the NobleCon 14 Annual Investor Conference on January 30, 2018

Englewood Cliffs, New Jersey, USA- January 23, 2018 – Immune Pharmaceuticals Inc. (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that its CEO, Elliot Maza, will present at NobleCon14- Noble Capital Markets’ Fourteenth Annual Investor Conference, to be held January 29-30 at the W Hotel in […]

Keep Reading

PRESS RELEASE January 10, 2018

Immune Pharmaceuticals Announces Acceptance of Late-Breaking Abstract at the American Academy of Dermatology Annual Meeting 2018

Oral Presentation to Include Positive Interim Results from its Ongoing Phase 2 Trial of Bertilimumab in Bullous Pemphigoid Englewood Cliffs, NJ- January 10, 2018 – Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (the “Company”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that an abstract detailing positive interim […]

Keep Reading

PRESS RELEASE January 4, 2018

Immune Pharmaceuticals to Present at the Biotech Showcase™ Annual Conference on January 10, 2018

Englewood Cliffs, NJ- January 4,2018 – Immune Pharmaceuticals Inc. (NASDAQ: IMNP), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that it will present at Biotech Showcase ™ 2018, to be held January 8–10 during the most important week in healthcare investment forums at the Hilton San Francisco […]

Keep Reading

PRESS RELEASE December 11, 2017

Immune Pharmaceuticals Appoints John Zhang, MD, PhD as Vice President, Research and Development

Englewood Cliffs, NJ, USA – December 11, 2017 – Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that it has appointed John Zhang, MD, PhD to the position of Vice President, Research and Development. Dr. Zhang will have oversight […]

Keep Reading

PRESS RELEASE November 15, 2017

Immune Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides a Corporate Update

Englewood Cliffs, NJ – November 15, 2017 – Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (“Immune”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced financial results for the quarter ending September 30, 2017 and provided a corporate update. Third Quarter 2017 and Recent Highlights On October 23, we […]

Keep Reading

PRESS RELEASE October 23, 2017

Immune Pharmaceuticals Inc. Announces Closing of $18,000,000 Public Offering of Convertible Preferred Stock and Warrants

October 23, 2017 12:09 PM Eastern Daylight Time ENGLEWOOD CLIFFS, N.J.–(BUSINESS WIRE)–Immune Pharmaceuticals Inc. (“Immune”) (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced the closing of its previously announced public offering of units for gross proceeds of $18,000,000, which excludes underwriting discounts and commissions […]

Keep Reading